近日，上海生生医药冷链科技股份有限公司（下称"上海生生"）向港交所提交招股书。此前，公司曾递 表科创板，但最终无果而终。根据弗若斯特沙利文的报告，按2024年收入计，上海生生是中国市场排名 第一的制药及生命科学温控供应链服务提供商。在临床试验温控供应链这一细分领域，公司客户覆盖了 中国前20大制药公司的100%，以及全球前20大制药公司的50%。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 出品：新浪财经上市公司研究院 作者：天利 作为中国排名第一的制药及生命科学温控供应链服务商，上海生生身处创新药研发的黄金赛道，"卖水 人"故事颇具吸引力。但同时，对招股书等相关资料进行后发现，公司目前仍存在诸多隐忧，包括营收 增长停滞、业务结构高度集中、关联交易错综复杂以及实控人资本运作颇具争议等。 营收"止步不前"增长瓶颈隐现 毛利率走高背后财务真实性或存疑 从财务数据看，上海生生近年营收稳健增长，2023年、2024年及2025年前三季度分别为6.14亿元、6.54 亿元、5.38亿元。但将时间线拉长看，早在2021年，上海生生的收入就已经达到5.25亿元，2022年为 6.34亿元。由此 ...

Core Viewpoint - Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. is seeking to list on the Hong Kong Stock Exchange after previously withdrawing its A-share IPO application, citing the need for international expansion and a more accommodating market for profit fluctuations [1][5]. Financial Performance - The company has shown steady revenue growth but significant profit volatility over the past three years, with revenues of approximately 614.2 million RMB in 2023, 654.5 million RMB in 2024, and 538.0 million RMB in the first nine months of 2025. Net profits were 92.0 million RMB, 26.4 million RMB, and 113.0 million RMB respectively [2][4]. - In 2024, revenue increased by 6.56% year-on-year, but profits dropped by 70% due to a rise in share-based payment expenses and increased sales and administrative costs [2][4]. Business Model and Market Position - Shanghai Shengsheng is a provider of integrated temperature-controlled supply chain services in the pharmaceutical and life sciences sector, focusing on clinical trial temperature control services, which account for over 82% of its revenue [6][10]. - The company is the largest domestic provider of clinical trial temperature-controlled supply chain services and ranks among the top ten globally, serving over 7,000 clients and supporting more than 4400 new drug clinical trial applications [10]. Growth Opportunities - The company plans to use IPO proceeds to expand its operations both domestically and internationally, including the establishment of new regional operational centers and clinical drug warehouses [11]. - The innovative drug sector is experiencing high growth, with a record number of new drug approvals and significant market activity, which may benefit Shanghai Shengsheng's business [8]. Challenges - The company faces high customer concentration, with the top five clients accounting for an increasing percentage of sales, which poses a risk if key client relationships change [5]. - Trade receivables have been growing, indicating potential cash flow pressures, with the turnover days extending from 98 to 105 days [5]. - The company is also exploring new applications for its temperature control technology in advanced manufacturing and renewable energy sectors, but these markets present different challenges and may not yield immediate results [12]. Conclusion - While Shanghai Shengsheng is well-positioned in a growing industry with a solid business model, it must navigate significant operational challenges and market competition to achieve sustainable growth and develop new revenue streams [13].

Core Viewpoint - Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, facing scrutiny over internal control issues despite its industry advantages and market position [1] Group 1: Company Overview - Shanghai Shengsheng is a leading integrated temperature-controlled supply chain service provider in the pharmaceutical and life sciences sector, focusing on clinical trial temperature-controlled supply chain services [2] - The company achieved revenues of 614 million yuan, 654 million yuan, and 538 million yuan for the years 2023, 2024, and the first three quarters of 2025, respectively, with profits of 92.03 million yuan, 26.396 million yuan, and 113 million yuan during the same periods [2] - The revenue structure is primarily derived from clinical trial temperature-controlled supply chain services, which consistently account for over 80% of total revenue [2] Group 2: Market Dynamics - The growth in Shanghai Shengsheng's performance is driven by the expanding market size and technological demands, with the clinical trial temperature-controlled service market in China growing from 2 billion yuan in 2020 to 3.6 billion yuan in 2024 [3] - The company holds both GMP and GDP certifications, establishing a nationwide service network to meet the stringent temperature control and safety requirements of the pharmaceutical industry [3] Group 3: Financial Performance and Challenges - The accounts receivable of Shanghai Shengsheng increased significantly, with trade receivables of 157 million yuan, 192 million yuan, and 220 million yuan during the reporting period, and the turnover days for trade receivables were 98 days, 98 days, and 105 days, respectively [4] - The company acknowledged that some transactions with clients are settled on credit, which could adversely affect its cash flow and business operations if clients fail to pay on time [4] Group 4: Governance Issues - Concerns regarding internal control governance arose when the actual controllers borrowed funds to increase their shareholding and subsequently transferred shares at a premium, raising regulatory scrutiny [5] - The significant difference in share transfer prices has led to questions from regulators, although the company has stated that there are reasonable backgrounds for these price variations [5] - In 2024, the company reported a substantial drop in profits primarily due to share-based payment expenses amounting to 72.12 million yuan, with a significant portion of these expenses attributed to a few high-salaried employees [6]

Core Viewpoint - Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. has submitted an IPO application to the Hong Kong Stock Exchange after previously withdrawing its application from the Shanghai Stock Exchange in June 2024 [1] Group 1: Company Overview - Shanghai Shengsheng is a leading integrated temperature-controlled supply chain service provider in the pharmaceutical and life sciences industry, focusing on clinical trial temperature-controlled supply chain services and extending to commercialized medical product temperature-controlled supply chain services [2] - The company is ranked as the number one temperature-controlled supply chain service provider in China and is the only Chinese company among the top ten global clinical trial temperature-controlled supply chain service providers [2] - The company has served over 7,000 clients, including top biopharmaceutical and biotechnology companies, central laboratories, CROs, and CDMOs [2] Group 2: Operational Capabilities - Shanghai Shengsheng possesses both GMP and GDP qualifications and has established a service network across major cities in China, with over 130 operational sites and more than 40 regional operation centers, covering 99% of prefecture-level cities [3] - The company has also set up regional operation centers in overseas markets, providing services in over 70 countries and regions [3] Group 3: Financial Performance - The company reported revenues of 614.2 million RMB and 654.5 million RMB for the years 2023 and 2024, respectively, with profits of 92.0 million RMB and 26.4 million RMB [4] - For the first three quarters of 2025, the company achieved a revenue of 538.7 million RMB, representing a year-on-year growth of 10.97%, and a profit of 113.0 million RMB, reflecting a year-on-year increase of 68.6% [4] Group 4: Use of IPO Proceeds - The funds raised from the IPO will be used to expand and upgrade the company's domestic and international supply chain service network, enhance temperature control technology and digital capabilities, and support potential strategic investments and acquisitions [4]

Core Viewpoint - Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, seeking to expand its business internationally after previously withdrawing its A-share IPO application [1][2][3]. Company Overview - Established in 2009, Shanghai Shengsheng focuses on temperature-controlled supply chain services for clinical trials and is the leading provider in China and one of the top ten globally [4]. - The company reported revenues of approximately 614.19 million RMB, 654.49 million RMB, and 538.71 million RMB for the fiscal years 2023, 2024, and the first three quarters of 2025, respectively [5]. Financial Performance - For the fiscal year 2023, the company achieved a profit of 92.03 million RMB, which is expected to decline by 70% in 2024 [5]. - The sales and marketing expenses increased by 56.8%, administrative expenses rose by 96.1%, and R&D expenses grew by 4.6% in 2024 compared to the previous year [5]. Trade Receivables - The company has highlighted potential adverse impacts on its financial performance due to the recoverability of trade receivables, which amounted to approximately 158 million RMB, 192 million RMB, and 221 million RMB at the end of the reporting periods [6]. - The average collection period for trade receivables was 98 days for 2023 and 2024, increasing to 105 days in 2025 [6]. Shareholding Structure - The chairman, Ju Jibing, controls approximately 42.62% of the voting rights in the company, with his family and associated entities forming the controlling shareholder group [6]. Related Party Transactions - Ju Jibing and his spouse have previously engaged in significant borrowing from the company for equity acquisitions, totaling 74.66 million RMB [7][8]. - Notably, the couple's entity, Ningbo Yanjia, has been involved in both borrowing funds from the company and selling shares for cash [9].

Core Viewpoint - Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CICC and Guojin Securities (Hong Kong) as joint sponsors [1] Company Overview - Shanghai Shengsheng is an integrated temperature-controlled supply chain service provider in the pharmaceutical and life sciences industry, focusing on clinical trial temperature-controlled supply chain services and extending to commercialized medical product temperature-controlled supply chain services [3] - The company is ranked first in the Chinese market for pharmaceutical and life sciences temperature-controlled supply chain services and is the only Chinese company among the top ten global clinical trial temperature-controlled supply chain service providers [3][10] - The company has served over 7,000 clients, including leading biopharmaceutical and biotechnology companies, covering a wide range of drug categories [4] Financial Information - Revenue for the nine months ending September 30 for 2023, 2024, and 2025 was approximately RMB 614.2 million, RMB 654.5 million, and RMB 537.9 million, respectively [5] - Profit for the same periods was approximately RMB 92.0 million, RMB 26.4 million, and RMB 112.0 million, respectively [6][8] - Gross profit margins for the same periods were 32.9%, 32.9%, and 37.6% [8] Industry Overview - The global pharmaceutical and life sciences temperature-controlled supply chain services market has shown stable growth, with a projected increase from USD 20.7 billion in 2020 to USD 29.3 billion in 2024, representing a compound annual growth rate (CAGR) of 9.1% [10] - The Chinese market for pharmaceutical and life sciences temperature-controlled supply chain services is expected to grow from RMB 18.8 billion in 2020 to RMB 26.5 billion in 2024, with a CAGR of 9.0% [10] - The clinical trial temperature-controlled supply chain services market in China is expected to grow from RMB 2.0 billion in 2020 to RMB 3.6 billion in 2024, with a CAGR of 15.8% [11] Market Characteristics - The global clinical trial temperature-controlled supply chain services market has high entry barriers, with market share increasingly concentrated among a few leading companies [15] - The top ten market participants hold approximately 60.3% of the total market share, indicating a relatively high level of industry concentration [15][16]

Core Viewpoint - Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CICC and Guojin Securities (Hong Kong) as joint sponsors [1] Company Overview - Shanghai Shengsheng is an integrated temperature-controlled supply chain service provider in the pharmaceutical and life sciences industry, focusing on clinical trial temperature-controlled supply chain services and extending to commercialized medical product temperature-controlled supply chain services [2] - The company is ranked first in the Chinese market for pharmaceutical and life sciences temperature-controlled supply chain services and is the only Chinese company among the top ten global clinical trial temperature-controlled supply chain service providers [2][9] - The company has served over 7,000 clients, including leading biopharmaceutical and biotechnology companies, covering a wide range of drug categories [3] Financial Information - Revenue for the nine months ending September 30 for 2023, 2024, and 2025 was approximately RMB 614.2 million, RMB 654.5 million, and RMB 537.9 million, respectively [4] - Profit for the same periods was approximately RMB 92.0 million, RMB 26.4 million, and RMB 112.0 million, respectively [5][6] - Gross profit margins for the same periods were 32.9%, 32.9%, and 37.6% [7] Industry Overview - The global pharmaceutical and life sciences temperature-controlled supply chain services market has shown stable growth, with a market size expanding from USD 20.7 billion in 2020 to USD 29.3 billion in 2024, representing a CAGR of 9.1% [9] - The Chinese market for pharmaceutical and life sciences temperature-controlled supply chain services is projected to grow from RMB 18.8 billion in 2020 to RMB 26.5 billion in 2024, with a CAGR of 9.0% [9] - The clinical trial temperature-controlled supply chain services market in China is expected to grow from RMB 2.0 billion in 2020 to RMB 3.6 billion in 2024, with a CAGR of 15.8% [10] Market Characteristics - The global clinical trial temperature-controlled supply chain services market has high entry barriers, with market share increasingly concentrated among a few leading companies [14] - The top ten market participants hold approximately 60.3% of the total market share, indicating a relatively high level of industry concentration [14]

Group 1 - The core viewpoint of the article is that Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CICC and Guotai Junan Securities (Hong Kong) as joint sponsors [1] - Shanghai Shengsheng is recognized as a leading integrated temperature-controlled supply chain service provider in the pharmaceutical and life sciences industry in China, focusing on temperature-controlled supply chain services for clinical trials and extending to commercialized medical product services [1] - According to a report by Frost & Sullivan, Shanghai Shengsheng ranks first in the Chinese market for pharmaceutical and life sciences temperature-controlled supply chain services and is the only Chinese company among the top ten global clinical trial temperature-controlled supply chain service providers [1]